Work

New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy

Year: 2012

Type: article

Abstract: Although standard therapy for AML has been relatively constant over the past 2 decades, this may be changing with enhanced technologies allowing for the classification of acute myeloid leukemia (AML) into molecularly distinct subsets. Some specific subsets of AML have an excellent prognosis in response to standard therapy, whereas the poor prognosis of AML associated with specific sets of mutations or chromosomal anomalies requires the development of new therapies. Elucidation of the molecular pathogenesis of AML has led to the development of therapies that affect signaling, apoptosis, protein and intermediate metabolism, the surface of the leukemia cell, leukemia cell/stromal interaction, and epigenetic regulation of gene expression.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-12-0313

Authors: Irum Khan, Jessica K. Altman, Jonathan D. Licht

Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences